×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Skin Cancer

WAYNE KUZNAR
Novel immunotherapies either release the immune system’s parking brake or hit its gas pedal.
GINA BATTAGLIA, PH.D.
Oncolytic, or engineered, viruses that infect and kill cancer cells are showing promise.
MEERI KIM, PH.D.
Checkpoint inhibitors can be extremely effective for the right patients, but identifying who will benefit remains an imprecise science.
Andrew Smith
A new expert guideline for managing immunotherapy’s side effects has been released.
Katie Kosko
Study findings published in the Journal of the American Academy of Dermatology showed that once-daily aspirin use can increase the risk of melanoma in men — nearly double that of men who do not use aspirin each day.
Kristie L. Kahl
Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Brielle Urciuoli
Age shouldn't be a determining factor in giving a patient with melanoma immunotherapy. In fact, one study found that older patients actually do better on checkpoint blockades.
Barbara Tako
Recognize birthdays, but most importantly, keep hope, says a breast cancer and melanoma survivor.
Jason M. Broderick
The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion, according to Bayer and Loxo Oncology, the codevelopers of the pan-TRK inhibitor. 
Brielle Urciuoli
Recent research, conducted at NYU Langone Health and presented at the Oncology Nursing Society (ONS) Annual Congress, sought to find out how patients with melanoma perceived skin health education, and their willingness be involved in their own surveillance or a loved one’s.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other